Autonomix Medical Reports New Topline Results From First 15 Patients' 7-Day Data Highlighting Significant Impact On Treatment Of Pancreatic Cancer Pain With Maintained Pain Reduction; 79% Responder Rate Achieved With Zero Opioid Use And Quality Of...
Autonomix Medical Reports New Topline Results From First 15 Patients' 7-Day Data Highlighting Significant Impact On Treatment Of Pancreatic Cancer Pain With Maintained Pain Reduction; 79% Responder Rate Achieved With Zero Opioid Use And Quality Of...
Autonomix Medical Reports New Topline Results From First 15 Patients' 7-Day Data Highlighting Significant Impact On Treatment Of Pancreatic Cancer Pain With Maintained Pain Reduction; 79% Responder Rate Achieved With Zero Opioid Use And Quality Of Life Improvement At 7 Days Post-Procedure; Clinically Meaningful Mean Of 4.96 Or 63% Reduction Of Pain On The VAS Pain Scale Was Observed
Autonomix醫療報告首批15名患者7天數據新的上線結果，突出對胰腺癌疼痛治療的重大影響，保持疼痛減輕；79%的響應率在零鴉片類藥物使用情況下實現，並在手術後7天改善生活質量；VAS疼痛評分上觀察到臨床意義的平均4.96或63%的疼痛減輕
79% responder rate achieved with zero opioid use and quality of life improvement at 7 days post-procedure
79%的響應率在零鴉片類藥物使用情況下實現，並在手術後7天改善生活質量
Company reaches 60% enrollment with 15 patients1 successfully enrolled; No unexpected complications or procedural-related significant adverse events
公司招募60%的患者，成功招募了15名患者；沒有出現意外併發症或與手術相關的重大不良事件
Clinically meaningful mean of 4.96 or 63% reduction of pain on the VAS pain scale was observed
VAS疼痛評分上觀察到臨床意義的平均4.96或63%的疼痛減輕
THE WOODLANDS, TX, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced preliminary positive results from the first 15 patients in the Company's ongoing proof-of-concept human clinical trial (the "Trial") evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.
德州伍德蘭市，2024年10月31日（全球新聞社） - Autonomix Medical, Inc.（納斯達克：AMIX）（「Autonomix」或「公司」），一家專注於推動創新技術，從事如何診斷和治療涉及神經系統的疾病的醫療器械公司，今日宣佈該公司進行中的概念板塊人類臨床試驗（「試驗」）中首批15名患者的初步積極結果，評估向胰腺癌疼痛患者傳遞經血管的能源以消融相關的問題神經並減輕疼痛的安全性和有效性。
譯文內容由第三人軟體翻譯。
